Cómo funciona la asistencia
Optimizando la experiencia de farmacia especializada de nuestros pacientes con una comodidad de servicio completo sin igual
-
1. Verifique su cobertura/verificación de beneficios
Nuestro equipo de facturadores expertos encuentra las mejores vías de cobertura que minimizan los costos de bolsillo.
-
2. Transferir receta a AmeriPharma®
Procesamos su receta trabajando con su farmacia o prescriptor anterior, haciendo que la transición sea rápida y sencilla.
-
3. Autorización previa
Nuestro equipo de especialistas obtiene la aprobación de sus compañías de seguros en un plazo de 24 a 72 horas.
-
4. Asistencia para copagos y ayuda financiera
Garantizamos ayuda financiera y reducimos copagos, gastos de bolsillo y deducibles elevados. Hasta la fecha, AmeriPharma® Specialty Care ha obtenido $55 millones en asistencia financiera para nuestros pacientes.
-
5. Coordinación de atención de enfermería si es necesario
AmeriPharma® prioriza su agenda y su entorno hogareño al programar y coordinar una de nuestras enfermeras especializadas para sus infusiones en el hogar.
-
6. Coordinación de entrega
Los medicamentos se entregan siempre en estricto cumplimiento de los requisitos específicos de envío. Las entregas con cadena de frío al día siguiente y al día siguiente se coordinan según su horario.
What Is Neupogen?
Neupogen (filgrastim) is an injectable medicine used to treat or prevent neutropenia (low neutrophil levels) in certain patients, including people receiving cancer treatments like chemotherapy. Neutropenia is a condition in which your body has a low white blood cell count, particularly neutrophils, which fight bacterial and fungal infections. Neupogen helps reduce the risk of infections by stimulating neutrophil production in cancer patients.
Neupogen (filgrastim) is manufactured by Amgen and was aprobado por la FDA in 1991. Currently, five biosimilars of this drug are available in the market, including Filkri, Nivestym, Nypozi, Releuko, and Zarxio.
The FDA has approved Neupogen (filgrastim) for several uses, including:
- To reduce the risk of serious infections due to a low white blood cell count in people with certain types of cancer (non-myeloid) who received chemotherapy.
- To help neutrophils recover faster after intensive chemotherapy in patients with acute myeloid leukemia (AML).
- To help the cancer patient’s neutrophil count recover more quickly after bone marrow or stem-cell transplantation.
- To move blood-forming stem cells from the bone marrow into the bloodstream before patients undergo stem-cell collection therapy.
- When a person has persistently or repeatedly low neutrophils, such as congenital neutropenia, cyclic neutropenia, y idiopathic neutropenia.
- To stimulate bone marrow recovery after severe radiation exposure, which has severely damaged blood-cell production.
- To increase survival in patients exposed to bone marrow-suppressing radiation.
Neupogen: Mode of Action (MOA)
When cancer patients receive high-dose chemotherapy treatment, it also damages the bone marrow cells, which results in a significant reduction in the number of white blood cells, including neutrophils, in the blood circulation.
Since the cancer patient’s bone marrow needs time to produce new infection-fighting white blood cells, these patients are at high risk of serious infection due to neutropenia (low neutrophil counts).
Neupogen (filgrastim) speeds up neutrophil production. Neupogen is a factor estimulante de colonias de granulocitos (G-CSF), which the body also produces naturally. G-CSF normally acts on the bone marrow and boosts the production of neutrophils.
Neupogen works like the body’s natural G-CSF, helping white blood cells mature faster into neutrophils and enter the bloodstream to fight bacteria and reduce infection risk.
Neupogen: Drug Form
Neupogen is available as a liquid solution in both single-dose vials and single-dose prefilled syringes in the following strengths:
- Single-dose vials: 300 mcg/ml and 480 mcg/1.6 ml
- Prefilled syringe: 300 mcg/0.5 ml and 480 mcg/0.8 ml
How Neupogen Copay Assistance Works
La farmacia especializada AmeriPharma® alivia las cargas financieras de los pacientes y sus familias.
-
Un software avanzado localiza fuentes de financiación para conectarlo con programas de fundaciones de alto valor
-
Uno de nuestros especialistas en asistencia de copagos le ayudará con el proceso de solicitud.
-
Se le enviarán a usted y a su médico actualizaciones automáticas sobre el estado de la financiación.
Dosis recomendada
Your doctor determines the dosage and duration of Neupogen based on your condition, treatment, and blood-cell counts. Recommended dosages vary depending on the condition being treated:
1. Dosage for Cancer Patients Receiving Chemotherapy
The recommended initial dosage for patients with AML or non-myeloid cancers receiving chemotherapy is 5 mcg/kg/day, which can be administered as a single daily subcutaneous injection, by short intravenous infusion (15 to 30 minutes), or by continuous intravenous infusion.
2. Dosage for Cancer Patients Undergoing Bone Marrow Transplantation
The recommended dosage of Neupogen following bone marrow transplantation (BMT) is 10 mcg/kg/day, which is given as an intravenous infusion no longer than 24 hours. The first dose should be administered at least 24 hours after chemotherapy and at least 24 hours after bone marrow infusion.
3. Dosage for Patients Undergoing Bone Marrow Collection Therapy
For collecting a patient’s own stem cells from the blood, Neupogen is given as a subcutaneous injection under the skin at a dosage of 10 mcg/kg/day. The first dose is given at least 4 days before the first leukapheresis procedure and continues until the last leukapheresis.
4. Dosage for Patients with Severe Chronic Neutropenia
The initial dosage of Neupogen in patients with congenital neutropenia is 6 mcg/kg, given as a subcutaneous injection twice a day. In patients with idiopathic or cyclic neutropenia, the dosage is 5 mcg/kg as a single daily subcutaneous injection.
5. Dosage for Patients Exposed to Bone Marrow-Suppressing Radiation
For patients who are exposed to myelosuppressive doses of radiation, a dose of 10 mcg/kg is given as a single daily subcutaneous injection. The Neupogen should be administered as soon as possible after suspected or confirmed exposure to radiation doses greater than 2 gray (Gy).
Neupogen Side Effects
Efectos secundarios comunes:
The most common side effects of Neupogen vary depending on the condition being treated and how the medication is used. For instance:
- Patients with non-myeloid cancers receiving chemotherapy may experience fever, pain, rash, cough, and shortness of breath.
- Patients with Acute myeloid leukemia receiving chemotherapy may have pain, nosebleeds, and rash.
- Non-myeloid cancer patients receiving chemotherapy followed by bone marrow transplant may have rash.
- People having their own blood cells collected may have bone pain, fever, and headache.
- Patients with severe chronic neutropenia may have pain, decreased red blood cells, nosebleeds, diarrhea, reduced sensation, and hair loss.
Efectos secundarios graves:
- rotura del bazo
- Acute respiratory distress syndrome (a serious lung problem)
- Reacciones alérgicas graves
- Sickle cell crises in people with sickle cell disorder
- lesión renal
- Síndrome de fuga capilar (CLS)
- Síndrome mielodisplásico (SMD) y leucemia mieloide aguda (LMA)
- Decreased platelet count (thrombocytopenia)
- Increased white blood cell count (leukocytosis)
- Inflammation of your blood vessels (cutaneous vasculitis)
- Inflammation of arteries (arteritis)
Seguros aceptados
Aceptamos Medicare, Medicaid multiestatal, Medi-Cal, Blue Shield y la mayoría de los seguros privados. Llámenos para obtener más información sobre su cobertura.
Comience en minutos
Complete sus datos y uno de nuestros especialistas le llamará lo antes posible.
¿Cuánto puedes ahorrar?
Complete este formulario para ahorrar hasta 100%!
Al enviar, acepta los términos y condiciones de AmeriPharma. Condiciones de uso, política de privacidad, y Aviso de prácticas de privacidad